Global site navigation

Local editions

Sanofi improves outlook on strength of bestseller Dupixent
Business and Economy

Sanofi improves outlook on strength of bestseller Dupixent

by  AFP 1 min read
In the first nine months of the year, revenue reached 32.3 billion euros
In the first nine months of the year, revenue reached 32.3 billion euros. Photo: Thomas SAMSON / AFP
Source: AFP

PAY ATTENTION: You can save a live of girl at risk. Donate to Legit Charity on Patreon. Your support matters!

French drug maker Sanofi has revised its outlook for 2022 upwards after reporting strong sales growth in the third quarter on Friday.

While Sanofi faced struggles in producing a jab against Covid, its Dupixent drug, which treats conditions including asthma and eczema, has been a huge success.

In Q3, sales of Dupixent exceeded the two billion euros mark for the first time, Sanofi said in a statement.

The pharmaceutical giant was also boosted by nearly two billion euros of sales for its flu vaccines, as many countries prepare for the peak winter flu season.

Sanofi said between July and the end of September, net profit fell 10 percent to two billion euros ($2 billion) due to impairments.

But without exceptional items net profit jumped 32 percent to 3.6 billion euros, higher than expected by analysts.

Read also

Air France-KLM Q3 turnover above pre-Covid levels

PAY ATTENTION: Subscribe to Digital Talk newsletter to receive must-know business stories and succeed BIG!

And in the first nine months of the year, revenue reached 32.3 billion euros -- an increase of more than 16 percent.

Sanofi now expects earnings per share (EPS) -- a measure of a company's profitability -- of around 16 percent for this year, up from earlier predictions.

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.

Hot: